Article

Lymphoma Expert Suggests Asking About Clinical Trials Soon After Diagnosis

Author(s):

Radhakrishnan Ramchandren, M.D.

Radhakrishnan Ramchandren, M.D., from the Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, discusses the role of clinical trials in developing news drugs and standards of care for patients with lymphoma.

Radhakrishnan Ramchandren, M.D., from the Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, discusses the role of clinical trials in developing news drugs and standards of care for patients with lymphoma.

In particular, Ramchandren acknowledged that the success from these trials should not be underestimated or underemphasized. In turn, this is why patients should be evaluated for clinical trials and discuss potential eligibility, especially given the landscape of lymphoma, he said.

Related Videos
Dr. Sattva S. Neelapu, a professor and deputy department chair in the Department of Lymphoma/Myeloma, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center, in Houston, as well as a member of Graduate Faculty, Immunology Program, Graduate School of Biomedical Sciences, at The University of Texas Health Science Center, also located in Houston.
Dr. Michael Bogenschutz, director of the NYU Langone Center for Psychedelic Medicine in New York,
Dr. Richard “Rick" Winneker
Dr Sattva S. Neelapu discusses data from the ZUMA-5 trial investigating the CAR T-cell therapy Yescarta in relapsed/refractory follicular lymphoma
Image of man with grey hair.
Image of woman with blonde hair.
Image of man with grey hair.
Image of man with brown and grey hair.
Image of man with grey hair.
Image of bald man in suit.
Related Content
CAR-T Cell Therapy in Hematologic Malignancies
January 6th 2025

Understanding the Intricacies of CAR-T Cell Therapy and Care in Hematologic Malignancies

Ryan Scott
Dr. Sattva S. Neelapu discusses the intricacies of CAR T-cell therapy treatment and care for patients with hematologic malignancies.
CURE Cancer Horizons podcast logo
January 29th 2024

Prostate Cancer Headlines, CAR-T Warnings and Laughter Therapy

Alex Biese Brielle Benyon
CURE® editors discuss last week’s biggest cancer headlines, from Dexter Scott King’s death to the potential of laughter therapy to boost quality of life.
Image of woman with blondish hair.
December 30th 2024

Empowering Patients With Cancer Through Clear Clinical Trial Communication

Darlene Dobkowski, MA
A clinical trial manager emphasizes the importance of a phased approach to educating patients about complex protocols and potential side effects.
Top Headlines on CAR-T Cell Therapy
December 4th 2023

Top Headlines on CAR-T Cell Therapy

Alex Biese Brielle Benyon
From FDA concerns to a potential new drug, CAR-T cell therapies were dominating oncology headlines last week.
Illustration of red cell.
December 25th 2024

Monjuvi Combination May Improve Survival in Follicular Lymphoma

Caroline Seymour
Monjuvi plus Revlimid and Rituxan demonstrated improved progression-free survival for patients with relapsed or refractory follicular lymphoma.
Image of Jace.
December 24th 2024

Jace Yawnick of Jace Beats Cancer on the ‘Roller Coaster’ of Life in Remission

Alex Biese
After sharing his cancer story online, Jace Yawnick is in a state of technical remission after receiving a diagnosis of non-Hodgkin lymphoma at age 25.